Get the Stockscreener App
10.55
6.57%
0.65
Amicus Therapeutics Inc stock is traded at $10.55, with a volume of 11.13M.
It is up +6.57% in the last 24 hours and up +12.00% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.90
Open:
$9.92
24h Volume:
11.13M
Relative Volume:
2.20
Market Cap:
$3.26B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-86.12
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
+6.57%
1M Performance:
+12.00%
6M Performance:
+70.99%
1Y Performance:
+3.94%
1-Day Range:
$9.78
$11.00
1-Week Range:
$9.725
$11.00
52-Week Range:
$5.51
$11.00
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
10.55 | 3.05B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month HighStill a Buy? - MarketBeat
Amicus Therapeutics Capitalizes on Strategic Expansion and Surges in Stock Price - StocksToTrade
Amicus Therapeutics’ Stock Benefits from Financial Resilience Despite Marginal Decline - timothysykes.com
Analyst Upgrade: Is Amicus Therapeutics Inc stock a smart buy before Fed meetingJuly 2025 Fed Impact & Low Risk Entry Point Guides - moha.gov.vn
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy’ Reco - MSN
683 Capital Management LLC Acquires 685,000 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics stock hits 52-week high at 10.61 USD By Investing.com - Investing.com Nigeria
Amicus Therapeutics stock hits 52-week high at 10.61 USD - Investing.com
Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? - Finviz
Redmile Group LLC Sells 8,344,671 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Osterweis Capital Management Inc. Sells 573,805 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Jump Financial LLC Raises Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
How Amicus Therapeutics Inc. (FOLD) Affects Rotational Strategy Timing - news.stocktradersdaily.com
3,235,538 Shares in Amicus Therapeutics, Inc. $FOLD Bought by Norges Bank - MarketBeat
Amicus Therapeutics, Inc. $FOLD Shares Sold by JPMorgan Chase & Co. - MarketBeat
Can Galafold continue to drive Amicus' top line in 2026? - MSN
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prudential Financial Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock - Finviz
Can Galafold Continue to Drive Amicus' Top Line in 2026? - Yahoo Finance
Schroder Investment Management Group Purchases 649,177 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
What is the fair value estimate for Amicus Therapeutics Inc. (AM6) stock in 2025Quarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - Newser
Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares - MarketBeat
Is Amicus Therapeutics Inc. (AM6) stock nearing a technical breakout2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
How Amicus Therapeutics Inc. (AM6) stock performs in volatility spikes2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Pompe Disease Treatment Market is expected to reach US$ 4.06 - openPR.com
Amicus Therapeutics CEO Sells Shares - TradingView
What analysts say about Amicus Therapeutics Inc stockStock Valuation Metrics & We Spotted the Next Tesla – See Inside - earlytimes.in
Will Amicus Therapeutics Inc. (AM6) stock benefit from mergersLong Setup & Safe Capital Growth Stock Tips - Newser
Capital Fund Management S.A. Has $4.37 Million Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Will Amicus Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Highlights & Reliable Entry Point Trade Alerts - Newser
Why Amicus Therapeutics Inc. (AM6) stock could break out in 2025Recession Risk & Daily Profit Maximizing Tips - Newser
Amicus Therapeutics, Inc. $FOLD Stock Position Raised by Virtus Investment Advisers LLC - MarketBeat
Creative Planning Purchases 180,652 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Advantage Alpha Capital Partners LP Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month - Yahoo Finance
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook - Yahoo Finance
Intech Investment Management LLC Sells 47,907 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc. $FOLD Stock Holdings Increased by Jefferies Financial Group Inc. - MarketBeat
Geode Capital Management LLC Sells 57,278 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Envestnet Asset Management Inc. Has $368,000 Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
David Michael Clark Sells 25,643 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Selling: Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 14,587 Shares of Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 95,565 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics chief people officer sells $258,932 in stock By Investing.com - Investing.com UK
Insider Sell Alert: David Clark Sells 25,643 Shares of Amicus Th - GuruFocus
Amicus Therapeutics chief legal officer sells $958k in stock By Investing.com - Investing.com Canada
Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet - Finviz
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):